TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02082236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Arm A: Sufenta®
Description: Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Sufentanil SSM 30 mcg
Description: single-dose SSM 30 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: SSM 15 mcg
Description: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: SSM 30 mcg
Description: 12 consecutive doses of SSM 30 mcg administered 1 hour apart
Study: NCT03551964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor: IV bolus 30 μg/kg (application \< 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.~* Cangrelor therapy will be stopped after circulatory stabilization - when sBP \> 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI~* 30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.
Study: NCT01688414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoacoustic imaging
Description: Undergo PAI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo fluorescence imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robot-assisted laparoscopic surgery
Study: NCT03998254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V503
Description: 9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
Study: NCT02926131

Intervention type: OTHER
Intervention: Blood sampling
Description: * One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system
Study: NCT02411682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast eating (YesB)
Description: On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast eating (YesB)
Description: On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast skipping (NoB)
Description: On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast skipping (NoB)
Description: On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
Study: NCT00594126

Intervention type: DRUG
Group type: OTHER
Intervention: Imetelstat Sodium (GRN163L)
Description: 25% dose escalation infused over 2 hours weekly
Study: NCT03023228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes self-management education
Description: 1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
Study: NCT04334733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope group
Description: The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope group
Description: The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon+Kaleidoscope group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon+Kaleidoscope group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
Study: NCT05409833

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD
Description: Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD
Description: Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
Study: NCT03478150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc oxide nano-particles
Description: The zinc oxide nano-powder will be mixed with ethanol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser diode
Description: The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
Study: NCT02235974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-acute intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual and Customary Care only. No additional therapy will be given during the 1-year study.
Study: NCT01322048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Propranolol and Per Tube Clonidine
Description: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV q6h and Per Tube q12, both for 7 days
Study: NCT00047203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT00679588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin Sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study: NCT00233805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated Bx Velocity™
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal Bx Velocity™
Description: bare-metal stent
Study: NCT02466438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: * Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician
Study: NCT00846339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: bupropion
Study: NCT04209699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose
Study: NCT00561496

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir gel
Description: Intravaginal (4grams)single dose followed by fourteen days

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir gel
Description: Intravaginal (4grams)single dose followed by fourteen days
Study: NCT00647322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of anti-epileptic medications
Description: Reduction in anti-epileptic medications

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No drug change
Description: No change in anti-epileptic treatment
Study: NCT01257789

Intervention type: PROCEDURE
Intervention: laparoscopic gastric bypass
Description: laparoscopic gastric bypass
Study: NCT04461808

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: tomosynthesis + synthetic 2D
Description: Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: digital mammography
Description: Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography.
Study: NCT00300781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study: NCT00909792

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Silicone hydrogel, soft, multifocal contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Silicone hydrogel, soft, multifocal contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Silicone hydrogel, soft, multifocal contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Silicone hydrogel, soft, multifocal contact lens
Study: NCT05188326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza 100 milligram (mg) injection
Description: 1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best supportive care includes antibiotics, transfusions and fluids
Study: NCT02284048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ticagrelor
Description: compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
Study: NCT00719563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01868113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroid
Description: Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered 12hourly
Study: NCT01141348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: 16 week behavioral weight loss intervention included 2 hour weekly group sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Description: During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
Study: NCT02781272

Intervention type: PROCEDURE
Intervention: Pelvic imaging
Description: Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.

Intervention type: PROCEDURE
Intervention: Imaging guided biopsy, surgical biopsy or surgical excision
Description: Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
Study: NCT02700204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay 532nm fractional treatment
Description: is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay 1064nm fractional treatment
Description: is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
Study: NCT01856166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Release analgesia by CADD SMITHS PCEA pump
Description: Analgesia will be release by continuous manner with an automatic pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release analgesia by CADD SMITHS PIEB pump
Description: Analgesia will be release by bolus with an automatic pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Study: NCT02823756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Exercise, education, spinal manipulation
Study: NCT03224325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet T2
Description: Tak-831 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet T2
Description: Tak-831 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet T2
Description: Tak-831 tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: TAK-831 placebo-matching suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Suspension
Description: TAK-831 Suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Suspension
Description: TAK-831 Suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Suspension
Description: TAK-831 Suspension.
Study: NCT03259594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic deroofing
Description: The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic deroofing
Description: The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 g of amino acids supplementation
Description: intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 100 g of amino acids supplementation
Description: intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
Study: NCT00849719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a combination of PCA MO and continuous infusion of MO
Description: Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA MO only
Description: When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Study: NCT00474669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
Study: NCT01012843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate
Description: oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo tablets two times a day for 10 days
Study: NCT01774851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-111
Description: MM-111 (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab (IV)
Study: NCT02762825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
Study: NCT02183636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/pioglitazone, FDC formulation C5
Description: film coated tablet (5 mg/45 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/pioglitazone, FDC formulation C8
Description: film coated tablet (5 mg/45 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin tablet
Description: 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone tablet (Actos®)
Description: 45 mg
Study: NCT02354898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg twice daily (800mg total daily dose)
Study: NCT04145661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids programmed conventionally.
Description: All participants will wear their hearing aids programmed in this way for around six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids programmed conventionally.
Description: All participants will wear their hearing aids programmed in this way for around six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids programmed with compression activated.
Description: All participants will wear their hearing aids programmed in this way for around six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids programmed with compression activated.
Description: All participants will wear their hearing aids programmed in this way for around six weeks.